| 摘要 |
Methods for treating cystic kidney disease are described. The method includes administering to a subject having, or susceptible to, the disease, an effective amount of a renal therapeutic agent or polynucleotide encoding the protein. Renal therapeutic agents are isolated, renal therapeutic molecules that preferably are selected from a member of an osteogenic protein/bone morphogenic protein (OP/BMP) family within a transforming growth factor-beta superfamily of proteins. A particulary preferred agent has at least 60 % amino acid sequence homology with the group consisting of SEQ ID NOS: 1-5. |
